Th17 helper cell and T-cell immunoglobulin and mucin domain 3 involvement in GuillainBarré syndrome

Immunopharmacology and Immunotoxicology

Volumn 34, Issue 6, 2012, Pages 1039-1046

  Liang, Song Lan ^a   Wang, Wei Zhi ^a   Huang, Shuo ^a   Wang, Xiao Kun ^a   Zhang, Suang ^a   Wu, Yun ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

GuillainBarr syndrome; IL 17; ROR t; Th17; TIM 3

Indexed keywords

BETA ACTIN; GAMMA INTERFERON; INTERLEUKIN 17; MEMBRANE PROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; RETINOID RELATED ORPHAN RECEPTOR GAMMA; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN 3 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOSTIMULATION; LYMPHOCYTE COUNT; MALE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH1 CELL; TH17 CELL; TH2 CELL;

ADULT; CELL DIFFERENTIATION; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; RNA, MESSENGER; TH1 CELLS; TH17 CELLS; TH2 CELLS; YOUNG ADULT;

EID: 84868111908     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2012.697469     Document Type: Article

References (36)

1. Ang C.W., Jacobs B.C., Laman J.D. The Guillain-Barrusyndrome: a true case of molecular mimicry. Trends Immunol 2004;25:1-6.
2. Irie, S., Saito, T., Nakamura, K., Kanazawa, N., Ogino, M., Nukazawa, T., Ito, H., Tamai, Y., Kowa, H. Association of anti-GM2 antibodies in Guillain-Barrusyndrome with acute cytomegalovirus infection. J Neuroimmunol 1996, 68, 19-26.
3. Dilley, A., Gregson, N.A., Hadden, R.D., Smith, K.J. Effects on axonal conduction of anti-ganglioside sera and sera from patients with Guillain-Barrusyndrome. J Neuroimmunol 2003, 139, 133-140.
4. van den Berg, L.H., Marrink, J., de Jager, A.E., de Jong, H.J., van Imhoff, G.W., Latov, N., Sadiq, S.A. Anti-GM1 antibodies in patients with Guillain-Barrusyndrome. J Neurol Neurosurg Psychiatr 1992, 55, 8-11.
5. Lardone, R.D., Yuki, N., Odaka, M., Daniotti, J.L., Irazoqui, F.J., Nores, G.A. Anti-GM1 IgG antibodies in Guillain-Barrusyndrome: fine specificity is associated with disease severity. J Neurol Neurosurg Psychiatr 2010, 81, 629-633.
6. Nyati, K.K., Prasad, K.N., Rizwan, A., Verma, A., Paliwal, V.K. TH1 and TH2 response to Campylobacter jejuni antigen in Guillain-Barre syndrome. Arch Neurol 2011, 68, 445-452.
7. Oikawa, T., Kamimura, Y., Akiba, H., Yagita, H., Okumura, K., Takahashi, H., Zeniya, M., Tajiri, H., Azuma, M. Preferential involvement of Tim-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host disease. J Immunol 2006, 177, 4281-4287.
8. van de Weyer PS, Muehlfeit M, Klose C, Bonventre JV, Walz G, Kuehn EW. A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9. Biochem Biophys Res Commun. 2006;351:571-576.
9. Zhu, C., Anderson, A.C., Kuchroo, V.K. TIM-3 and its regulatory role in immune responses. Curr Top Microbiol Immunol 2011, 350, 1-15.
10. Anderson, A.C., Anderson, D.E. TIM-3 in autoimmunity. Curr Opin Immunol 2006, 18, 665-669.
11. Frisancho-Kiss S., Nyland J.F., Davis S.E., et al. Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J Immunol 2006;1766:6411-6415.
12. Sehrawat, S., Suryawanshi, A., Hirashima, M., Rouse, B.T. Role of Tim-3/galectin-9 inhibitory interaction in viral-induced immunopathology: shifting the balance toward regulators. J Immunol 2009, 182, 3191-3201.
13. Monney, L., Sabatos, C.A., Gaglia, J.L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E.A., Coyle, A.J., Sobel, R.A., Freeman, G.J., Kuchroo, V.K. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002, 415, 536-541.
14. S?chez-Fueyo, A., Tian, J., Picarella, D., Domenig, C., Zheng, X.X., Sabatos, C.A., Manlongat, N., Bender, O., Kamradt, T., Kuchroo, V.K., Guti?rez-Ramos, J.C., Coyle, A.J., Strom, T.B. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 2003, 4, 1093-1101.
15. Dong, C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008, 8, 337-348.
16. Louten, J., Boniface, K., de Waal Malefyt, R. Development and function of TH17 cells in health and disease. J Allergy Clin Immunol 2009, 123, 1004-1011.
17. Hastings, W.D., Anderson, D.E., Kassam, N., Koguchi, K., Greenfield, E.A., Kent, S.C., Zheng, X.X., Strom, T.B., Hafler, D.A., Kuchroo, V.K. TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J Immunol 2009, 39, 2492-2501.
18. Nakae, S., Iwakura, Y., Suto, H., Galli, S.J. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol 2007, 81, 1258-1268.
19. Solt, L.A., Kumar, N., Nuhant, P., Wang, Y., Lauer, J.L., Liu, J., Istrate, M.A., Kamenecka, T.M., Roush, W.R., Vidovic, D., Schuer, S.C., Xu, J., Wagoner, G., Drew, P.D., Griffin, P.R., Burris, T.P. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 2011, 472, 491-494.
20. Hwang, E.S. Transcriptional regulation of T helper 17 cell differentiation. Yonsei Med J 2010, 51, 484-491.
21. Furuzawa-Carballeda, J., Vargas-Rojas, M.I., Cabral, A.R. Autoimmune inflammation from the Th17 perspective. Autoimmun Rev 2007, 6, 169-175.
22. Asbury, A.K., Cornblath, D.R. Assessment of current diagnostic criteria for Guillain-Barrusyndrome. Ann Neurol 1990, 27 Suppl, S21YS24.
23. van der Mechu F.G., Schmitz, P.I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barrusyndrome. Dutch Guillain-BarruStudy Group. N Engl J Med 1992, 326, 1123-1129.
24. Sabatos, C.A., Chakravarti, S., Cha, E., Schubart, A., Schez-Fueyo, A., Zheng, X.X., Coyle, A.J., Strom, T.B., Freeman, G.J., Kuchroo, V.K. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 2003, 4, 1102-1110.
25. Yang, L., Anderson, D.E., Kuchroo, J., Hafler, D.A. Lack of TIM-3 immunoregulation in multiple sclerosis. J Immunol 2008, 180, 4409-4414.
26. Zhu, C., Anderson, A.C., Schubart, A., Xiong, H., Imitola, J., Khoury, S.J., Zheng, X.X., Strom, T.B., Kuchroo, V.K. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005, 6, 1245-1252.
27. Koguchi, K., Anderson, D.E., Yang, L., O'Connor, K.C., Kuchroo, V.K., Hafler, D.A. Dysregulated T cell expression of TIM3 in multiple sclerosis. J Exp Med 2006, 203, 1413-1418.
28. Wang, F., Wan, L., Zhang, C., Zheng, X., Li, J., Chen, Z.K. Tim-3-Galectin-9 pathway involves the suppression induced by CD4+CD25+ regulatory T cells. Immunobiology 2009, 214, 342-349.
29. Khademi, M., Ill, Z., Gielen, A.W., Marta, M., Takazawa, N., Baecher-Allan, C., Brundin, L., Hannerz, J., Martin, C., Harris, R.A., Hafler, D.A., Kuchroo, V.K., Olsson, T., Piehl, F., Wallstr, E. T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol 2004, 172, 7169-7176.
30. Wang, F., He, W., Yuan, J., Wu, K., Zhou, H., Zhang, W., Chen, Z.K. Activation of Tim-3-Galectin-9 pathway improves survival of fully allogeneic skin grafts. Transpl Immunol 2008, 19, 12-19.
31. Sellge, G., Magalhaes, J.G., Konradt, C., Fritz, J.H., Salgado-Pabon, W., Eberl, G., Bandeira, A., Di Santo, J.P., Sansonetti, P.J., Phalipon, A. Th17 cells are the dominant T cell subtype primed by Shigella flexneri mediating protective immunity. J Immunol 2010, 184, 2076-2085.
32. Fitzgerald, D.C., Ciric, B., Touil, T., Harle, H., Grammatikopolou, J., Das Sarma, J., Gran, B., Zhang, G.X., Rostami, A. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J Immunol 2007, 179, 3268-3275.
33. Ichiyama, K., Yoshida, H., Wakabayashi, Y., Chinen, T., Saeki, K., Nakaya, M., Takaesu, G., Hori, S., Yoshimura, A., Kobayashi, T. Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J Biol Chem 2008, 283, 17003-17008.
34. Fantini, M.C., Rizzo, A., Fina, D., Caruso, R., Becker, C., Neurath, M.F., Macdonald, T.T., Pallone, F., Monteleone, G. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol 2007, 37, 3155-3163.
35. Sonderegger, I., Kisielow, J., Meier, R., King, C., Kopf, M. IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo. Eur J Immunol 2008, 38, 1833-1838.
36. Wang, W. (ed.), Neurology. Beijing, China: People's Medical Publishing House, 2006.